News & Articles

FEATURED ARTICLE

Virus-Like Particles (VLPs): Structure, Expression & Immune Response

Virus-like particles (VLPs) are nanoparticle structures (50-300nm diameter) that mimic the organization and conformation of authentic native viruses but lack the viral genome...

August 20, 2024
Read more

Browse articles by topic:

Neoantigen-Based Immunotherapy: Unveiling Disease-Specific Targets

Neoantigen-Based Immunotherapy: Unveiling Disease-Specific Targets

August 20, 2024

3 min read

Introducing Neoantigen-Based Immunotherapy Neoantigen-based immunotherapy is revolutionizing cancer treatment by focusing on neoantigens—unique proteins formed by mutations in cancer cells....

Read more →
Webinar: Transforming Tumor Research: Engineering MHCs as Versatile Reagents

Webinar: Transforming Tumor Research: Engineering MHCs as Versatile Reagents

December 20, 2023

Speaker Dr. Manhee Suh, Co-founder & CTO, KACTUS What's Inside When dealing with solid tumors lacking specific biomarkers, the effectiveness...

Read more →
Transforming Tumor Research: Engineering MHCs as Versatile Reagents

Transforming Tumor Research: Engineering MHCs as Versatile Reagents

September 7, 2023

1 min read

ManHee Suh's Talk @ CAR-TCR Summit We are delighted to share with you our experience at the 8th CAR-TCR Summit...

Read more →
Cell and antibody therapies targeting HLA-G

Cell and antibody therapies targeting HLA-G

February 14, 2023

3 min read

On December 19, 2022, the FDA approved the Phase I/IIa clinical trial application of IVS-3001, an anti-HLA-G CAR-T cell therapy...

Read more →
TCR therapy targeting MAGE-A4

TCR therapy targeting MAGE-A4

January 2, 2023

1 min read

Figure 1. MAGE-A4 Protein Recently at the 2022 CTOS Conference, Adaptimmune announced the SPEARHEAD-1 clinical trial data of its TCR-T...

Read more →
CDH17: A Safe CAR-T Target for Treatment of Solid Tumors

CDH17: A Safe CAR-T Target for Treatment of Solid Tumors

July 19, 2022

4 min read

Chimeric antigen receptor T cell (CAR-T) therapy has been successful in the field of hematological malignancies, but it is not...

Read more →